Catalent

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

CTLT reports Q3 revenue decline, eyes growth in gene therapy

CTLT faced challenges in the Biologics segment and adjusted its fiscal 2023 guidance due to operational and COVID-related issues. However, the company's capacity and healthy pipeline in the gene therapy business present opportunities for growth. The company is also evaluating divestitures to reduce debt load and is focused on improving financial rigor in the upcoming fiscal year.

Catalent reports solid Q2 earnings, eyes gene therapy expansion

Catalent's Q2 performance was solid, with a focus on collaborations, ESG initiatives, and strong market positioning. Challenges in the supply chain and COVID revenue assumptions were notable, but opportunities in gene therapy and core business growth are promising. The company remains optimistic about future growth and strategic partnerships.

Catalent adjusts guidance, targets cost savings amid operational challenges

Catalent focused on improving productivity and cost structure to return to historical margin levels.
Addressing investor concerns on regulatory inspections and confident in corrective actions.
Expecting significant cost savings in fiscal '24 and targeting positive cash generation.
Operational challenges in Q3 impacting financials in Q4, with a focus on improving profitability.

Catalent addresses challenges, eyes growth in gene therapy and GLP-1

Catalent navigated fiscal challenges, focusing on growth areas like gene therapy and GLP-1 projects. The company aims to address financial performance, operational efficiency, and strategic reviews to enhance shareholder value and sustain growth.

Catalent reports solid Q1 performance amidst revenue challenges and growth opportunities

Catalent's Q1 performance was solid despite revenue decline from COVID.
The company is focusing on growth drivers like gene therapy and GLP-1 demand.
Challenges include revenue concentration risks and capacity constraints.
Opportunities lie in new business wins, tech transfer completion, and strategic improvements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalent (CTLT) agrees to buy Mayne Pharma's specialty CDMO division, Metrics Contract Services, for $475 million. The deal is expected to be completed by 2022-end.

Catalent (CTLT) to Acquire New CDMO Facility for $475 Million

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in Greenville, North Carolina, for $475 million from Mayn

Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Capabilities and Oral Development and Manufacturing Capacity

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that it will release financial results for the fourth quarter of fiscal year 2022 ended June 30, 2022, before the market open on Monday, August 29, 2022. The Company's management will host a webcast to discuss the results at 8:15 a.m. E

Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast

Assertio Therapeutics Inc

ASRT vs. CTLT: Which Stock Is the Better Value Option?

The expansion of primary packaging capabilities in Japan is expected to drive significant growth for Catalent in coming years. Recently, Catalent announced a new operating structure in which the company has consolidated the four segments into two: Biologics and Pharmaceuticals & Consumer Health.

Catalent: Primary Packaging Capability Expansion To Drive Growth

HEICO

Eli Lilly

Cheniere Energy

Lantheus Holdings

New Fortress Energy

Ollie's Bargain Outlet Hlds

Quanta Services

UnitedHealth Group

Vertex Pharmaceuticals

With earnings due, IBD Leaderboard stocks like Eli Lilly, Vertex and Ollie's test bases, breakouts and buy zones. The post Watch These Leaders With Earnings Due, Buy Zones In Focus appeared first on Investor's Business Daily.

Watch These Leaders With Earnings Due, Buy Zones In Focus

California Resources

Alphabet

Kirin Holdings Co Ltd

Taiwan Semiconductor Manufacturing

The Seeking Alpha Quant system has its quirks, but it is a great tool to find great holdings. I typically dredge through the weeds to find unique situations that may be unloved by the quant system.

5 Real Growth 'Strong Buys'

Catalent Inc (NYSE:CTLT) is a multinational company that enables pharma, biotech, and consumer health partners to optimize product development, launch, and supply of treatments for patients around the world.

A Technical Look at Catalent Stock After Last Week's Big Update

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced changes to its operating structure and executive leadership team that went into effect July 1. This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company rev

Catalent Announces New Operating Structure

Catalent's (CTLT) latest capability expansion is expected to boost its business in this key hub in its Asia-Pacific Clinical Supply Services network.

Catalent (CTLT) Expands Packaging Capabilities at Japan Facility

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.

Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine

Quanterix

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), has been appointed to Quanterix' Board of Directors effective June 6, 2022. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management expe

Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?

Catalent (CTLT) Up 0.4% Since Last Earnings Report: Can It Continue?

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will present at two upcoming investor conferences. On June 7, 2022 at 1:00 p.m. ET, the Company will present at the William Blair Annual Growth Stock Conference. On June 8, 2022, at 8:00 a.m. ET, the Company wil

Catalent, Inc. to Present at June Investor Conferences

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

Catalent's (CTLT) latest site expansion is expected to significantly boost its business.

Catalent's (CTLT) Latest Facility Expansion to Boost Capacity

Catalent's (CTLT) latest launch is expected to provide a reliable, reproducible and scalable path to clinic to its customers.

Catalent's (CTLT) New Launch to Enhance Gene Therapy Development

Catalent is the right combination for the 2022 environment with growth and stability - growing earnings and a diversified revenue base. All product categories have shown strength with strong potential for a rebound in shares with the stock at a P/E discount.

Buy Catalent After Undeserved Selloff

Catalent Inc (NYSE: CTLT) reported Q3 FY22 sales of $1.27 billion, +21% Y/Y as reported, or 23% in constant currency, edging out analysts' average expectation of $1.22 billion. Adjusted EPS of $1.04, compared to $0.82 last year, surpassed the consensus of $0.94.

Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook

Catalent, Inc. (NYSE:CTLT ) Q3 2022 Earnings Conference Call May 3, 2022 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Chiminski - Chair and Chief Executive Officer Alessandro Maselli - President and Chief Operating Officer Thomas Castellano - Senior Vice President and Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Luke Sergott - Barclays Capital Jacob Johnson - Stephens, Inc. Julia Qin - J.P. Morgan Sean Dodge - RBC Capital Markets Dave Windley - Jefferies John Sourbeer - UBS Justin Bowers - Deutsche Bank Jack Meehan - Nephron Research Operator 00:05 Hello and welcome to the Catalent, Inc. Third Quarter Fiscal Year 2022 Earnings Conference Call.

Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2022 Results - Earnings Call Transcript

Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.

Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up

Catalent (CTLT) delivered earnings and revenue surprises of 10.64% and 4.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced financial results for the third quarter of fiscal 2022, which ended March 31, 2022. “We are pleased with our strong results in the third quarter and our plans to continue to expand our capabilities to address long-term customer needs as our end

Catalent, Inc. Reports Third Quarter Fiscal 2022 Results

Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for Catalent Stock (CTLT)